These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments. Marchetti A; Magar R; Fischer J; Sloan E; Fischer P Clin Ther; 1996; 18(5):953-66. PubMed ID: 8930434 [TBL] [Abstract][Full Text] [Related]
4. Inappropriate fosphenytoin use in the ED. Johnson J; Wrenn K Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516 [TBL] [Abstract][Full Text] [Related]
5. Phenytoin and fosphenytoin: a model of cost and clinical outcomes. Armstrong EP; Sauer KA; Downey MJ Pharmacotherapy; 1999 Jul; 19(7):844-53. PubMed ID: 10417033 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED. Aaronson PM; Belgado BS; Spillane JP; Kunisaki TA Am J Emerg Med; 2011 Nov; 29(9):983-8. PubMed ID: 20685063 [TBL] [Abstract][Full Text] [Related]
7. A comparison of phenytoin-loading techniques in the emergency department. Swadron SP; Rudis MI; Azimian K; Beringer P; Fort D; Orlinsky M Acad Emerg Med; 2004 Mar; 11(3):244-52. PubMed ID: 15001403 [TBL] [Abstract][Full Text] [Related]
8. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department. Touchette DR; Rhoney DH Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551 [TBL] [Abstract][Full Text] [Related]
9. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Coplin WM; Rhoney DH; Rebuck JA; Clements EA; Cochran MS; O'Neil BJ Neurol Res; 2002 Dec; 24(8):842-8. PubMed ID: 12500711 [TBL] [Abstract][Full Text] [Related]
10. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370 [TBL] [Abstract][Full Text] [Related]
11. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Fischer JH; Patel TV; Fischer PA Clin Pharmacokinet; 2003; 42(1):33-58. PubMed ID: 12489978 [TBL] [Abstract][Full Text] [Related]
12. Pharmacoeconomic considerations in treatment options for acute seizures. Graves N J Child Neurol; 1998 Oct; 13 Suppl 1():S27-9; discussion S30-2. PubMed ID: 9796750 [TBL] [Abstract][Full Text] [Related]
14. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. Knapp LE; Kugler AR J Child Neurol; 1998 Oct; 13 Suppl 1():S15-8; discussion S30-2. PubMed ID: 9796747 [TBL] [Abstract][Full Text] [Related]
15. Fosphenytoin: a novel phenytoin prodrug. Boucher BA Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074 [TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage. Kim DW; Kim TE; Ji M; Chun YI Clin Neuropharmacol; 2015; 38(6):248-51. PubMed ID: 26536021 [TBL] [Abstract][Full Text] [Related]
17. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. DeToledo JC; Ramsay RE Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus. Srivastava K; Bhartiya S; Gavli V; Patil R; Rajadhyaksha S Indian Pediatr; 2020 Mar; 57(3):218-221. PubMed ID: 32198860 [TBL] [Abstract][Full Text] [Related]